Expert Cardiology Services: Cardiac Pacing & Electrophysiology — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cardiac pacing and electrophysiology is the subspecialty of cardiology focused on the diagnosis, investigation, and treatment of disorders of the heart's electrical conduction system. The heart's specialised electrical tissues — the sinoatrial (SA) node (the natural pacemaker), atrioventricular (AV) node, His bundle, bundle branches, and Purkinje fibres — generate and conduct electrical impulses that coordinate sequential atrial and ventricular contraction. Disorders affecting these tissues produce bradyarrhythmias (dangerously slow heart rates), tachyarrhythmias (abnormally rapid or irregular rhythms), or conduction abnormalities that impair cardiac function.

Cardiac electrophysiology (EP) services operate through two primary treatment modalities: device therapy and catheter ablation. Device therapy involves implanting small electronic systems — permanent pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronisation therapy (CRT) devices — in the chest wall and connecting them to the heart via leads, providing bradycardia pacing support, life-saving defibrillation therapy, or biventricular resynchronisation for heart failure patients with conduction delay. Catheter ablation uses energy delivered through fine catheters positioned within heart chambers to destroy small areas of tissue responsible for arrhythmia initiation or maintenance, offering the potential for long-term cure without the need for ongoing medication.

The cardiac electrophysiology laboratory (EP lab) is equipped with multi-channel electrophysiology recording systems, three-dimensional electroanatomical mapping platforms (CARTO, EnSite, Rhythmia), high-resolution fluoroscopy, and intracardiac echocardiography, enabling detailed electrophysiological assessment and guidance of complex ablation procedures. Leading EP programmes at tertiary cardiac centres perform over 500–1,000 ablation procedures per year, with procedural safety and success rates correlating strongly with institutional volume.

Pacing services manage bradyarrhythmias: sick sinus syndrome (inappropriate sinus bradycardia and pauses), symptomatic AV block (first-degree, Mobitz type 1 and 2 second-degree, complete third-degree heart block), bifascicular and trifascicular block with syncope, and chronotropic incompetence (failure of heart rate to increase appropriately with exercise). ICD services manage patients at high risk of sudden cardiac death from ventricular arrhythmias — including survivors of out-of-hospital cardiac arrest, patients with reduced LVEF below 35%, and those with heritable arrhythmia syndromes (hypertrophic cardiomyopathy, long QT syndrome, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy).

Catheter ablation services treat the full spectrum of supraventricular tachycardias (AVNRT, WPW, atrial flutter, focal atrial tachycardia, atrial fibrillation), ventricular ectopy causing symptoms or cardiomyopathy, and ventricular tachycardia (idiopathic and scar-related). CRT services manage patients with symptomatic heart failure, reduced LVEF (35% or less), and electrical dyssynchrony (QRS duration above 130 ms, particularly LBBB), providing biventricular pacing to coordinate ventricular contraction, improve cardiac output, and reverse adverse cardiac remodelling.

Permanent pacemaker implantation is indicated for symptomatic bradycardia (syncope, dizziness, breathlessness, exercise intolerance) attributable to documented sinus node dysfunction or AV conduction disease, and for complete heart block regardless of symptoms due to the risk of sudden asystole. ICD implantation is indicated as secondary prevention for all survivors of haemodynamically significant ventricular arrhythmias without a fully reversible cause, and as primary prevention for patients with ischaemic or non-ischaemic cardiomyopathy with LVEF below 35% despite at least 3 months of optimal medical therapy.

Catheter ablation is appropriate for patients with symptomatic arrhythmias where the targeted arrhythmia is amenable to a curative or high-success rate procedure, antiarrhythmic drug therapy has failed or not been tolerated, or a cure is preferred over lifelong medication. High-risk WPW syndrome (short anterograde refractory period in the accessory pathway, documented rapid pre-excited AF) requires urgent ablation. CRT is indicated in symptomatic HFrEF with LVEF 35% or less and QRS duration above 130 ms (particularly LBBB 150 ms or greater) despite optimal medical therapy for at least 3 months.

Modern EP services offer the full range of pacing technologies: single-chamber pacemakers, dual-chamber physiological pacemakers, leadless pacemakers (Micra), His bundle pacing, left bundle branch area pacing (for physiological resynchronisation), CRT-P and CRT-D, subcutaneous ICDs (S-ICD), and wearable cardioverter-defibrillators (WCD). Device selection is individualised based on the specific arrhythmia indication, degree of ventricular pacing dependency, need for defibrillation, left ventricular function, body habitus, and patient preference.

EP study — the diagnostic investigation preceding ablation — uses multiple recording catheters to map intracardiac electrograms, characterise arrhythmia mechanisms, and assess conduction system function. Advanced three-dimensional electroanatomical mapping systems (CARTO 3, EnSite X, Rhythmia) enable creation of detailed voltage and activation maps guiding precise ablation delivery. Contact force sensing catheters (SmartTouch, TactiCath) optimise tissue contact during ablation, reducing the number of non-transmural lesions and improving success rates. High-power short-duration (HPSD) ablation strategies deliver radiofrequency energy at higher power (50–90 W) for shorter durations, creating more consistent, deeper lesions with less char formation. Modern pacing technology offers conduction system pacing (His bundle and left bundle branch area pacing) as a physiologically superior alternative to conventional right ventricular pacing, delivering more natural ventricular activation. High-power short-duration radiofrequency delivery at higher power (50–90 W) for shorter durations, creating more consistent, deeper lesions with less char formation, has improved procedural efficiency in AF ablation.

EP services provide curative or substantially disease-modifying treatment for a wide range of cardiac arrhythmias. Permanent pacing eliminates symptoms of bradycardia in over 95% of appropriately selected patients and prevents life-threatening asystole in complete heart block. ICD therapy reduces sudden cardiac death risk by 23–31% in primary prevention patients with reduced LVEF, a benefit sustained for at least 5 years. CRT improves symptoms (at least one NYHA class improvement) in 60–70% of appropriately selected patients, reduces hospitalisations by 30–50%, and reduces all-cause mortality by 24–36%.

Catheter ablation provides curative treatment for the most common arrhythmias: AVNRT and accessory pathway ablation achieve cure rates of 95–97%; typical atrial flutter ablation 95%; AF ablation 70–80% single-procedure success for paroxysmal AF. The quality-of-life improvement from successful arrhythmia treatment is substantial — patients who have lived with frequent disabling palpitations, syncope, or breathlessness experience transformative relief of symptoms, restoration of normal activity, and elimination or reduction of long-term antiarrhythmic medication.

Device implantation risks include access-site haematoma (2–5%), pneumothorax (1%), lead displacement (1–3%), cardiac perforation (0.1–0.2%), and device pocket infection (0.5–1%). Long-term device complications include lead fracture or insulation failure (1–2% per lead per year), battery depletion requiring generator change, and inappropriate ICD shocks (5–15% annually with modern programming). Leadless pacemaker implantation carries a 1.5% risk of perforation, higher than conventional transvenous pacemakers.

Catheter ablation risks include pericardial tamponade (0.5–2%), stroke (0.1–0.5% for right-sided procedures, 0.5–1% for left-sided including AF ablation), complete AV block requiring pacemaker (less than 0.5% for most ablations, higher for para-Hisian pathways), pulmonary vein stenosis after AF ablation (1–3%), and atrioesophageal fistula (0.02–0.04% after AF ablation — rare but life-threatening). The specific risk profile for any individual patient depends on the arrhythmia, ablation approach, and patient anatomy, and is discussed in detail during the pre-procedural consent process.

Device implantation requires 1–2 days of hospitalisation. Wound and lead healing requires 4–6 weeks of restricted arm movement on the implant side. Remote monitoring — automatic wireless transmission of device-stored data — is now standard, enabling between-visit surveillance and early detection of device abnormalities, lead issues, and arrhythmia recurrences. In-person device clinic review occurs at 6 weeks, 6 months, and annually for stable patients, with additional visits triggered by remote monitoring alerts or patient symptoms.

Post-ablation recovery takes 2–5 days to return to normal activity. Post-AF ablation anticoagulation continues for 2 months minimum (indefinitely in high-stroke-risk patients). A 3-month blanking period is observed after AF ablation. Long-term rhythm monitoring (7-day Holter, extended monitoring, or implantable loop recorder) assesses success at 3, 6, and 12 months. Patients who experience arrhythmia recurrence after ablation are evaluated for repeat ablation, typically after at least 3 months from the first procedure.

Device implantation and catheter ablation procedures represent significant healthcare expenditure. In the United States, pacemaker implantation costs $15,000–$50,000; ICD $35,000–$80,000; CRT-D $60,000–$120,000; AF ablation $25,000–$50,000; and VT ablation $30,000–$60,000. In the UK, NHS provides these procedures free for eligible patients; private costs range from £8,000 to £35,000 depending on procedure complexity.

For international patients, leading EP centres in India provide the full range of EP services — device implantation and catheter ablation including high-density mapping-guided AF and VT ablation — at 60–80% lower cost using internationally approved devices and technology. Pacemaker implantation at leading Indian centres costs $2,500–$6,000; ICD $8,000–$20,000; AF ablation $5,000–$10,000. Thailand, Turkey, and Singapore offer intermediate pricing options. All leading international EP centres use the same CARTO, EnSite, or Rhythmia mapping platforms and Medtronic, Abbott, Biotronik, or Boston Scientific devices as their Western counterparts.

For bradyarrhythmia, temporary transcutaneous pacing and atropine provide emergency management while awaiting permanent pacemaker implantation or resolution of reversible causes. In patients who decline pacemaker implantation, theophylline and oral sympathomimetics may provide modest heart rate support in sick sinus syndrome, though with limited efficacy. For arrhythmia management, antiarrhythmic drug therapy remains an alternative to catheter ablation, providing rate or rhythm control at the cost of ongoing medication side effects, compliance requirements, and lower long-term efficacy.

Conduction system pacing (His bundle or LBBA pacing) is emerging as an alternative to conventional biventricular CRT for cardiac resynchronisation, potentially providing more physiological activation patterns and avoiding some coronary sinus lead complications. Closed-loop stimulation pacemakers and rate-response algorithms for patients with chronotropic incompetence offer improved exercise heart rate responses compared to fixed-rate pacing. For patients with VT or VF in the context of acute ischaemia, coronary revascularisation (PCI or CABG) may abolish the arrhythmia substrate, rendering antiarrhythmic drugs or ablation unnecessary.